Tandem Diabetes Care, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $254.6 million (+5.8% year over year) and diluted EPS of -$0.31. It usually reports 37–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
255
+5.8%
|
-21
+59.6%
|
-0.31
+60.3%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
247
+5.5%
|
-20
+84.4%
|
-0.30
+84.8%
|
|
Feb 19, 2026
50 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
290
+2.7%
|
-1
-178.0%
|
-0.01
-200.0%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
249
+2.2%
|
-21
+9.0%
|
-0.31
+11.4%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
241
+8.5%
|
-52
-70.1%
|
-0.78
-66.0%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
234
+22.3%
|
-131
-205.6%
|
-1.97
-203.1%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
283
+43.6%
|
1
+102.5%
|
0.01
+102.2%
|
|
Nov 6, 2024
37 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
244
+31.4%
|
-23
+29.5%
|
-0.35
+31.4%
|
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TNDM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438133
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.